The growth drivers for one of Romania’s biggest pharmaceuticals plants are the assimilation of Uractiv portfolio from Romanian producer Fiterman Iasi, with the deal pending the antitrust authorities’ ok, as well as the launch of new products and higher exports for the products currently in the company’s portfolio.

“The year’s challenges are related to the clawback tax, the workforce crunch, the rising utilities, commodities and materials prices, the hurdles generated by the Ukraine war and the lack of dialogue with healthcare institutions, which are totally uninterested in Romania’s becoming more independent in the area of pharmaceuticals”, said Dragos Damian.

In the April 1 2021-March 31 2022 financial year, Terapia turnover reached RON865 million, up 11% from the previous year. Net profit also went up, to RON186 million, a 7.5% increase.

In the previous financial year, Terapia launched over 30 products on the local market and 10 new products for exports.

At present, the company’s portfolio comprises around 420 types of drugs.

(English version by Catalina Apostoiu)